National Cancer Institute In a nationwide study of women with triple-negative breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators reported at the 2013 San Antonio Breast Cancer Symposium.
Dec. 16, 2013 - National Cancer Institute
Additional Drug Shows Promise for Women with Triple-Negative Breast Cancer In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators will report at the 2013 San Antonio Breast Cancer Symposium.
Dec. 13, 2013 - Newswise
The Ovarian Cancer Drug Market is Set to More Than Double to $1.6 Billion by 2022 BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin will penetrate nearly all segments of the ovarian cancer market through 2022, driving growth of the angiogenesis inhibitor drug class and contributing to annual growth of approximately 10 ...
Dec. 11, 2013 - PR Newswire via Yahoo! Finance